Allarity Therapeutics is a clinical-stage precision medicine company based in Boston, MA, specializing in the development of personalized oncology therapeutics for patients with challenging-to-treat cancers. With their proprietary Drug Response Predictor (DRP) technology, they aim to enhance patient outcomes by refining patient selection and improving clinical outcomes.
The company's lead program, Stenoparib, is a dual-action small molecule inhibitor that targets both DNA damage repair enzymes PARP and key cell division and growth enzymes Tankyrase in tumor cells. Stenoparib has shown promising monotherapy activity in ovarian and pancreatic cancers and offers new hope to patients who have developed resistance to other PARP inhibitors. Allarity holds exclusive global rights for Stenoparib and is actively conducting clinical trials to explore its potential in multiple cancer types.
Generated from the website